Evidence map›Paper›PMID 38623593›Full record

ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2024

IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

Anni Sjöblom, Lauri Jouhi, Pirjo Laakkonen, Reija Randén-Brady, Jussi Tarkkanen, Caj Haglund, Petri Mattila, Timo Carpén, Jaana Hagström, Antti Mäkitie

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Anni SjöblomDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID https://orcid.org/0000-0003-1740-4346
Lauri JouhiDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pirjo LaakkonenTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Reija Randén-BradyDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jussi TarkkanenDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Caj HaglundTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Petri MattilaDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Timo CarpénDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jaana HagströmDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Antti MäkitieResearch Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIKarolinska University Hospital · SE

Funding

Ida Montinin SäätiöKorvatautien TutkimussäätiöMinerva FoundationSuomen Hammaslääkäriseura ApolloniaWellcome Trust 220089
6 · The paper itself

Abstract

Biomarkers are not broadly used in the management of head and neck cancers (HNCs). Biomarkers have been beneficial in the management of other cancers, however, not in HNCs. Therefore, we observed the immunopositivity of a novel biomarker called immunoglobulin superfamily member 3 (IGSF3) in tumor tissues in HPV-related and HPV-unrelated OPSCC. Two patient cohorts (C1 and C2) from separate time periods were available for this study (total N = 282). Both consisted of OPSCC patients treated at the Helsinki University Hospital (HUS, Helsinki, Finland) during 2000-2016. For HPV determination, HPV mRNA in situ hybridization was used. Immunohistochemistry was used to assess IGSF3 immunopositivity in cancer tissues. Overall survival (OS) was used as endpoint in the statistical analysis. In C1, stronger immunopositivity of IGSF3 in tumor-infiltrating lymphocytes (TILs) correlated with favorable OS (p = 0.005). Stronger IGSF3 immunopositivity in tumor cells (TCs) was associated with HPV negativity (p = 0.017). Stronger IGSF3 immunopositivity in TILs correlated with HPV positivity (p < 0.001). Elevated IGSF3 immunopositivity in TILs associates with HPV-related tumors and may signify favorable prognosis. The immunopositivity of IGSF3 differs between HPV-related and HPV-unrelated OPSCC.

Indexed as

Biomarkers, TumorPapillomavirus InfectionsAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleFinlandHumansImmunoglobulinsImmunohistochemistryIn Situ HybridizationLymphocytes, Tumor-InfiltratingMaleMembrane ProteinsMiddle AgedBiomarkers, TumorImmunoglobulinsMembrane ProteinsbiomarkerHPVimmunohistochemistryOPSCCprognosis

Identifiers

PMID38623593
PMCPMC11582339
OpenAlexW4394848176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.